Today: 10 December 2025
Subscribe
Browse Tag

Exact Sciences

Exact Sciences (EXAS) Stock: Abbott’s $23 Billion Deal, Q3 Earnings Beat and What Investors Should Watch Now

Exact Sciences (EXAS) Stock: Abbott’s $23 Billion Deal, Q3 Earnings Beat and What Investors Should Watch Now

Exact Sciences Corporation (NASDAQ: EXAS) has turned into one of the most closely watched healthcare stocks heading into December 2025, thanks to a blockbuster takeover agreement with Abbott Laboratories, strong Q3 results, and a rapid share‑price rally that has pushed
1 December 2025
 ·  ·  ·  ·  ·  · 
Exact Sciences (EXAS) Stock Today: Analyst Downgrades, Abbott’s $21 Billion Takeover and Legal Scrutiny – 25 November 2025

Exact Sciences (EXAS) Stock Today: Analyst Downgrades, Abbott’s $21 Billion Takeover and Legal Scrutiny – 25 November 2025

Exact Sciences Corporation (NASDAQ: EXAS) is trading near record highs as Wall Street shifts to “Hold,” merger-arb funds move in and shareholder lawyers start circling Abbott’s $21 billion bid. Exact Sciences Stock Price Snapshot for 25 November 2025 On Tuesday,
25 November 2025
 ·  ·  ·  ·  ·  · 
Exact Sciences (EXAS) Stock Today, November 24, 2025: Abbott Buyout Spread, Analyst Downgrades and UBS Target Hike

Exact Sciences (EXAS) Stock Today, November 24, 2025: Abbott Buyout Spread, Analyst Downgrades and UBS Target Hike

Dateline: November 24, 2025 Exact Sciences Corporation (NASDAQ: EXAS) stock is trading calmly near its takeover price today as Wall Street digests a flood of fresh analyst calls, legal scrutiny and local reaction to Abbott Laboratories’ multi‑billion‑dollar bid for the
24 November 2025
 ·  ·  ·  ·  ·  · 
Abbott Laboratories (ABT) to Buy Exact Sciences in Up to $23 Billion Cancer Diagnostics Deal – All the Key News on November 20, 2025

Abbott Laboratories (ABT) to Buy Exact Sciences in Up to $23 Billion Cancer Diagnostics Deal – All the Key News on November 20, 2025

Abbott Laboratories (NYSE: ABT) shook the healthcare and medtech markets today, November 20, 2025, by announcing a definitive agreement to acquire cancer diagnostics specialist Exact Sciences Corporation (NASDAQ: EXAS) in an all‑cash transaction valuing the target at about $21 billion
20 November 2025
 ·  ·  ·  ·  ·  · 
EXAS Stock Soars on Abbott Takeover Talks: Exact Sciences Jumps Over 20% on November 19, 2025

EXAS Stock Soars on Abbott Takeover Talks: Exact Sciences Jumps Over 20% on November 19, 2025

Exact Sciences Corporation (NASDAQ: EXAS) is surging today after reports that healthcare giant Abbott Laboratories is in advanced talks to acquire the cancer diagnostics specialist. Shares of EXAS spiked sharply intraday, briefly approaching new 52‑week highs as traders rushed into
19 November 2025
 ·  ·  ·  · 
Go toTop